77585-25-2

Basic information

• Product Name: 4-CHLOROPHENYL CYCLOBUTYL KETONE
• Synonyms: 4-CHLOROPHENYL CYCLOBUTYL KETONE;UKRORGSYN-BB BBV-5118688
• CAS NO: 77585-25-2
• Molecular Formula: C11H11ClO
• Molecular Weight: 194.66
• Mol File: 77585-25-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 303.9°C at 760 mmHg
• Flash Point: 154.6°C
• Appearance: /
• Density: 1.217g/cm³
• Vapor Pressure: 0.000904mmHg at 25°C
• Refractive Index: 1.576
• CAS DataBase Reference: 4-CHLOROPHENYL CYCLOBUTYL KETONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLOROPHENYL CYCLOBUTYL KETONE(77585-25-2)
• EPA Substance Registry System: 4-CHLOROPHENYL CYCLOBUTYL KETONE(77585-25-2)

Safety Data

• Hazardous Substances Data: 77585-25-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H11ClO/c12-10-6-4-9(5-7-10)11(13)8-2-1-3-8/h4-8H,1-3H2

Upstream product

• 104-88-1 4-chlorobenzaldehyde 
• 822-35-5 cyclobutene 
• 108483-22-3 (4-Chloro-phenyl)-(5,5-dimethyl-2-oxo-2λ⁵-[1,3,2]dioxaphosphinan-2-yl)-methanol 

Relevant articles and documents

Cobalt-Catalyzed Markovnikov-Selective Radical Hydroacylation of Unactivated Alkenes with Acylphosphonates

Acylphosphonates having the 5,5-dimethyl-1,3,2-dioxophosphinanyl skeleton are developed as efficient intermolecular radical acylation reagents, which enable the cobalt-catalyzed Markovnikov hydroacylation of unactivated alkenes at room temperature under mild conditions. The protocol exhibits broad substrate scope and wide functional group compatibility, providing branched ketones in satisfactory yields. A mechanism involving the Co-H mediated hydrogen atom transfer and subsequent trapping of alkyl radicals by acylphosphonates is proposed.

Methods and compositions for the treatment and prevention of sexual dysfunction

Methods are disclosed for the treatment and prevention of sexual. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3antagonists.

METHODS OF USING AND COMPOSITIONS COMPRISING SIBUTRAMINE METABOLITES OPTIONALLY IN COMBINATION WITH OTHER PHARMACOLOGICALLY ACTIVE COMPOUNDS

-